U.S. Office-based Labs Market (By Modality: Hybrid, Multi-specialty; By Service: Cardiac, Endovascular Intervention; By Specialist) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1.  Introduction

1.1.Research Objective

1.2.Scope of the Study

1.3.Definition

Chapter 2.  Research Methodology

2.1.Research Approach

2.2.Data Sources

2.3.Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.Introduction

4.2.Market Classification and Scope

4.3.Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Specialist Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5.  COVID 19 Impact on U.S. Office-based Labs Market

5.1.COVID-19 Landscape: U.S. Office-based Labs Industry Impact

5.2.COVID 19 - Impact Assessment for the Industry

5.3.COVID 19 Impact: Global Major Government Policy

5.4.Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6.  Market Dynamics Analysis and Trends

6.1.Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2.Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7.  Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1.  List of Suppliers

7.1.3.2.  List of Buyers

Chapter 8.  Global U.S. Office-based Labs Market, By Modality

8.1.U.S. Office-based Labs Market, by Modality Type, 2022-2030

8.1.1. Single-specialty Labs

8.1.1.1.  Market Revenue and Forecast (2017-2030)

8.1.2. Multi-specialty Labs

8.1.2.1.  Market Revenue and Forecast (2017-2030)

8.1.3. Hybrid Labs

8.1.3.1.  Market Revenue and Forecast (2017-2030)

Chapter 9.  Global U.S. Office-based Labs Market, By Service

9.1.U.S. Office-based Labs Market, by Service, 2022-2030

9.1.1. Peripheral Vascular Intervention

9.1.1.1.  Market Revenue and Forecast (2017-2030)

9.1.2. Endovascular Interventions

9.1.2.1.  Market Revenue and Forecast (2017-2030)

9.1.3. Cardiac

9.1.3.1.  Market Revenue and Forecast (2017-2030)

9.1.4. Interventional Radiology

9.1.4.1.  Market Revenue and Forecast (2017-2030)

9.1.5. Venous

9.1.5.1.  Market Revenue and Forecast (2017-2030)

9.1.6. Others

9.1.6.1.  Market Revenue and Forecast (2017-2030)

Chapter 10.Global U.S. Office-based Labs Market, By Specialist

10.1.U.S. Office-based Labs Market, by Specialist, 2022-2030

10.1.1.Vascular Surgeons

10.1.1.1.Market Revenue and Forecast (2017-2030)

10.1.2.Interventional Cardiologist

10.1.2.1.Market Revenue and Forecast (2017-2030)

10.1.3.Interventional Radiologists

10.1.3.1.Market Revenue and Forecast (2017-2030)

10.1.4.Others

10.1.4.1.Market Revenue and Forecast (2017-2030)

Chapter 11.Global U.S. Office-based Labs Market, Regional Estimates and Trend Forecast

11.1.North America

11.1.1.Market Revenue and Forecast, by Modality (2017-2030)

11.1.2.Market Revenue and Forecast, by Service (2017-2030)

11.1.3.Market Revenue and Forecast, by Specialist (2017-2030)

11.1.4.U.S.

11.1.4.1.Market Revenue and Forecast, by Modality (2017-2030)

11.1.4.2.Market Revenue and Forecast, by Service (2017-2030)

11.1.4.3.Market Revenue and Forecast, by Specialist (2017-2030)

11.1.5.Rest of North America

11.1.5.1.Market Revenue and Forecast, by Modality (2017-2030)

11.1.5.2.Market Revenue and Forecast, by Service (2017-2030)

11.1.5.3.Market Revenue and Forecast, by Specialist (2017-2030)

Chapter 12.Company Profiles

12.1.Koninklijke Philips N.V

12.1.1.Company Overview

12.1.2.Product Offerings

12.1.3.Financial Performance

12.1.4.Recent Initiatives

12.2.GE Healthcare

12.2.1.Company Overview

12.2.2.Product Offerings

12.2.3.Financial Performance

12.2.4.Recent Initiatives

12.3.Siemens Healthineers AG

12.3.1.Company Overview

12.3.2.Product Offerings

12.3.3.Financial Performance

12.3.4.Recent Initiatives

12.4.Medtronic PLC

12.4.1.Company Overview

12.4.2.Product Offerings

12.4.3.Financial Performance

12.4.4.Recent Initiatives

12.5.Boston Scientific Corp.

12.5.1.Company Overview

12.5.2.Product Offerings

12.5.3.Financial Performance

12.5.4.Recent Initiatives

12.6.Abbott

12.6.1.Company Overview

12.6.2.Product Offerings

12.6.3.Financial Performance

12.6.4.Recent Initiatives

12.7.Cardiovascular Systems, Inc.

12.7.1.Company Overview

12.7.2.Product Offerings

12.7.3.Financial Performance

12.7.4.Recent Initiatives

12.8.Envision Healthcare

12.8.1.Company Overview

12.8.2.Product Offerings

12.8.3.Financial Performance

12.8.4.Recent Initiatives

12.9.Surgery Care Associates, Inc. (SCA)

12.9.1.Company Overview

12.9.2.Product Offerings

12.9.3.Financial Performance

12.9.4.Recent Initiatives

12.10.Surgery Partners

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

12.11.National Cardiovascular Partners

12.11.1. Company Overview

12.11.2. Product Offerings

12.11.3. Financial Performance

12.11.4. Recent Initiatives

12.12.Cardiovascular Coalition

12.12.1. Company Overview

12.12.2. Product Offerings

12.12.3. Financial Performance

12.12.4. Recent Initiatives

12.13.TH Medical

12.13.1. Company Overview

12.13.2. Product Offerings

12.13.3. Financial Performance

12.13.4. Recent Initiatives

Chapter 13.Research Methodology

13.1.Primary Research

13.2.Secondary Research

13.3.Assumptions

Chapter 14.Appendix

14.1.About Us

14.2.Glossary of Terms